We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Effect of Azathioprine on Renal Histology and Function in Lupus Nephritis

Weldon D. Shelp, MD; J. M. B. Bloodworth Jr., MD; Richard E. Rieselbach, MD
Arch Intern Med. 1971;128(4):566-573. doi:10.1001/archinte.1971.00310220074008.
Text Size: A A A
Published online


The effectiveness of azathioprine was assessed in a longitudinal study of 12 selected patients with varying degrees of lupus nephritis. All had substantial histological evidence of disease (five with lupus glomerulitis and seven with lupus glomerulonephritis), and eight had an initial glomerular filtration rate of less than 80 ml/min 1.73 sq m. Clinical improvement or stability was observed in all patients and confirmed by serial renal clearance studies and protein excretion rates. Histologic evidence of acute glomerular involvement diminished in all patients, in association with the evolution of glomerulosclerosis. Seven patients were able to discontinue corticosteroids without clinical deterioration. Eight patients with initial renal insufficiency remained clinically stable with a mean survival of 32.5 months. Thus, azathioprine appears to offer considerable therapeutic benefit to selected patients with lupus nephritis.

Approximately 50% of patients with systemic lupus erythematosus (SLE) develop clinical evidence of renal disease, and about half of these succumb


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.